Painful sex? New treatment for menopausal women on its way to pharmacies

August 17, 2018 by Marcia Heroux Pounds, Sun Sentinel

For menopausal women who experience painful sex, a new treatment is on its way to pharmacies.

Boca Raton-based TherapeuticsMD began distributing its new product, Imvexxy, to stores recently. It will be available at all major retailers such as CVS, Walgreens and Walmart, as well as small pharmacies.

TherapeuticsMD, which is focusing on new health products for , received FDA approval in May to market Imvexxy. The vaginal gelcap insert was developed for who suffer from .

"We expect to have strong demand for the product," said John Milligan, president of TherapeuticsMD. "A lot of women are going to find it very effective for this condition."

A doctor's prescription is necessary to purchase Imvexxy, which costs about $35 in an insurance co-pay or with coupons online, said TherapeuticsMD CEO and co-founder Robert Finizio.

The FDA's approval of Imvexxy was based on the results of a Phase 3, double-blind clinical trial that evaluated the safety and efficacy of 4- and 10-microgram dosages, compared with a placebo for 12 weeks.

Milligan said as required by the FDA, TherapeuticsMD will do follow-up studies on women prescribed Imvexxy, as there is always a risk of endometrial cancer in women with a uterus who use estrogen-only therapy. Imvexxy's package label warns users to report any unusual vaginal bleeding to their doctor.

But the clinical trial showed that women who tried Imvexxy had "very little or no side effects," Finizio said. Some women reported headaches, breast tenderness or nausea, according to the site.

The treatment proved effective in "less than two weeks" for women participating in the clinical trial, Finizio added.

TherapeuticsMD has built an internal team of 250 sales representatives to introduce the treatment to physicians nationwide. It plans TV and web advertising.

For marketing purposes, executives were pleased that the FDA approved the name "Imvexxy," Milligan said. "It sounds close to 'I'm sexy,' which is a memorable name."

Competing products include Allergan's Estrace Cream, Pfizer's Premarin Cream and Novo Nordisk's Vagifem. There's also an oral medication, Duchesnay USA's Osphena.

TherapeuticsMD said its product is different from others on the market because it can be used any time of the day and requires no applicator. It also contains a low dose of estradiol, a form of the hormone estrogen.

Dr. Jay Cohen, an obstetrician-gynecologist in Plantation, said a low-dose estrogen treatment for vaginal dryness fills "a huge unmet need in this country." The condition affects about 32 million menopausal women in the United States, according to TherapeuticsMD.

"Fifty percent are sexually active into their late 70s," Cohen said. "A woman lives 20 to 30 years in menopause, and this gets worse and worse for women."

TherapeuticsMD was founded in 2008 and went public in 2016. Revenues in 2017 were $16.8 million, primarily from sales of the company's multivitamins, VitaMedMD, developed for pregnant women.

While the company is still losing money, Finizio said TherapeuticsMD could turn profitable over the following year, if new treatments are approved and new sales are successful.

TherapeuticsMD also is developing a proposed treatment for . The company hopes to receive an answer on marketing clearance from the FDA by the end of October.

That proposed treatment is in the form of one soft-gel capsule of estradiol, a form of estrogen, and progesterone. Today, many women have to take two different medications to treat hot flashes and other menopausal symptoms.

Also, in late July, TherapeuticsMD acquired the U.S. license to distribute a new contraceptive developed by Population Council, a New York-based, nonprofit research organization funded by the Bill & Melinda Gates Foundation. The agreement is contingent on the contraceptive being cleared by the FDA, which is anticipated in mid-August, Finizio said.

Milligan describes the contraceptive as a "long-acting vaginal system or ring that is patient-controlled." He said patients can take out the ring themselves, unlike an IUD that has to be inserted and removed by a doctor. "If you want to get pregnant, you take it out and stop using it," he said.

He thinks the product will be attractive to women who travel, those in the military, and college students.

The company last month announced a new partnership and license that could boost future sales.

TherapeuticsMD has partnered with Montreal-based Knight Therapeutics, a pharmaceutical company that is licensing Imvexxy and the proposed "hot flashes" treatment for distribution in Canada.

Knight made a $20 million investment in TherapeuticsMD, part of a recent $85 million round of financing. TherapeuticsMD has raised more than $500 million in private equity, according to Finizio.

TherapeuticsMD's stock price has ranged from $4.34 a share to $7.66 a share over 52 weeks in Nasdaq trading.

Some Wall Street analysts said the license and contraceptive would expand TherapeuticsMD's market to all the life stages of women, from child-bearing age to menopause.

TherapeuticsMD "sits in a unique position to consolidate assets in this space," wrote Annabel Samimy, managing director for specialty pharmaceuticals research at Stifel Financial Corp., in a report in early August.

Explore further: A new drug may help relieve menopausal vulvar and vaginal atrophy symptoms


Related Stories

A new drug may help relieve menopausal vulvar and vaginal atrophy symptoms

April 3, 2016
A new low-dose vaginal estrogen capsule may help relieve symptoms of menopausal vulvar and vaginal atrophy, including dyspareunia (pain during sex), new industry-sponsored research reports. The study results will be presented ...

Menopausal women experiencing distressing pain during sex

September 30, 2015
Results from qualitative research of postmenopausal women with vulvar and vaginal atrophy (VVA) show that they recognize the significant physical, emotional and psychological consequences of untreated dyspareunia (painful ...

Why isn't anyone talking about vaginal dryness (or doing anything about it)?

June 20, 2018
It's a common problem that only gets worse during the menopause transition; yet, no one wants to talk about it, and even fewer women are doing anything to correct it. A new study identifies those factors that contribute to ...

Vaginal estradiol tablets outperform moisturizers when treating vulvovaginal problems

May 9, 2018
Sex shouldn't hurt at any age, yet 75% of postmenopausal women report vaginal dryness, and up to 40% report pain with intercourse. A new study reports that vaginal estradiol tablets just might be what's needed to relieve ...

New natural estrogen-progesterone capsule reduces postmenopausal hot flashes

April 3, 2017
A natural, or bioidentical, combined estradiol-progesterone capsule (TX-001HR) significantly decreases the frequency and severity of moderate to severe hot flashes in postmenopausal women, the Replenish study finds. Results ...

Survey shows postmenopausal women with VVA report improved satisfaction with VagiCap

February 20, 2015
Newly released patient satisfaction survey results from a study of a novel investigational vaginal estrogen treatment show promise for improving quality of life and satisfaction for postmenopausal women who experience pain ...

Recommended for you

Soy formula feeding during infancy associated with severe menstrual pain in adulthood

November 9, 2018
New research suggests that infant girls fed soy formula are more likely to develop severe menstrual pain as young adults. The finding adds to the growing body of literature that suggests exposure to soy formula during early ...

A major role for a small organ in the immune response during pregnancy

November 9, 2018
The immune system of a pregnant woman is altered during pregnancy, but not in the way previously believed, according to results from a study at Linköping University, Sweden. This study, published in the Journal of Allergy ...

Mailed HPV tests can help find women at-risk for cervical cancer, study finds

November 7, 2018
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that mailing self-collection kits to test for high-risk human papillomavirus infection has the potential to boost cervical cancer ...

Women who give birth to boys much more likely to have postnatal depression

November 6, 2018
A University of Kent study into postnatal depression (PND) found the odds of developing this condition increased by 79% when mothers had baby boys compared to baby girls.

New study takes first step toward treating endometriosis

November 1, 2018
Researchers at Northwestern Medicine have taken the first step in bioengineering the human uterus to treat endometriosis, uterine-factor infertility and endometrial cancer.

Same-sex couple makes medical history by physically carrying the same embryo

October 31, 2018
They both helped carry their baby—and made medical history in the process.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Aug 17, 2018
Try Vazoplex. It is cheap and very effective. We have used it for at least 15 years with great success and no side effects. Just Google it.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.